Biotheryx Receives the US FDA’s IND Approval of BTX-9341 for Treating Breast Cancer
Shots:
- The US FDA has cleared the IND application of the company’s BTX-9341 to initiate the P-I clinical evaluation for treating breast cancer, in H2’24
- The P-I dose escalation study of BTX-9341 monotx. and in combination with fulvestrant aims at assessing its safety, biological activity and preliminary efficacy for treating HR+/HER2- breast cancer resistant to CDK4/6 inhibitor therapies
- BTX-9341 (oral) is a FIC, CDK4 and CDK6 degrader that inhibited Cyclin E and CDK2 transcription by potent and selectively degrading CDK4 and CDK6, leading to superior in vivo effectiveness in breast cancer xenografts
Ref: Biotheryx | Image: Biotheryx
Related News:- Biotheryx Entered into a Research Collaboration and License agreement with Incyte to Discover and Develop Targeted Protein Degraders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
